FDJ UNITED: Implementation of the Share Buyback Programme
BOULOGNE, France--(BUSINESS WIRE)--Regulatory News:
FDJ UNITED (Paris:FDJ):
On 22 May 2025, the Board of Directors decided to implement the share buyback programme adopted by the General Meeting of 22 May 2025 to serve the performance share plan (LTI) adopted on the same day and the employee share ownership transaction announced in the press release of 16 April 2025.
FDJ will entrust an investment services provider (ISP) with a mandate(s) to acquire a maximum of 455,000 shares over 3 years[1] in order to serve the LTI plan.
With regard to the employee shareholding operation, the acquisition will concern a maximum number of 1,852,700 shares and will be carried out before the settlement-delivery date of the offer reserved for employees, scheduled for 29 July 2025.
A description of the share buyback programme is provided in the 2024 Universal Registration Document (Chapter 7.2.2.1) available on the FDJ website (www.groupefdj.com).
About FDJ UNITED
FDJ UNITED is one of Europe's leading betting and gaming operators, with a vast portfolio of iconic brands and a reputation for technological excellence. With more than 5,000 employees and a presence in around fifteen regulated markets, the Group offers a diversified, responsible range of games, both under exclusive rights and open to competition: lottery games in France and Ireland, via an extensive point-of-sale network and online; sports betting at points of sale in France; and online games open to competition (sports and horse-race betting, poker and online casino games, in markets where these activities are authorized). FDJ Group has placed responsibility at the heart of its strategy and promotes recreational betting. FDJ Group is listed on the Euronext Paris regulated market (FDJU) and is a member of indices including the SBF 120, Euronext 100, Euronext Vigeo 20, EN EZ ESG L 80, STOXX Europe 600, MSCI Europe and FTSE Euro.
1 The maximum number of shares is calculated based on the estimate of the fair value of the FDJ share calculated by EY on 1 April 2025; the latter will be updated on 22 May 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Renewal of the drawdown under the Revolving Credit Facility for a six-month period
Press release 4 June 2025Renewal of the drawdown under the Revolving Credit Facility for a six-month periodParis, 4 June 2025 - Clariane ( - ISIN FR0010386334) announces that it has renewed the drawdown of its RCF (Revolving Credit Facility) for a period of 6 months for an amount of €490.8 million, in accordance with the terms of the contract signed February 14th, addition to the usual conditions, the Group points out that the drawdown and renewal of its RCF line are subject to a minimum liquidity level of €300 million on the day of the drawdown or renewal, which includes the RCF drawn down. This document contains forward-looking statements that involve risks and uncertainties, including those included or incorporated by reference, concerning the Group's future growth and profitability that could cause actual results to differ materially from those indicated in the forward-looking statements. These risks and uncertainties relate to factors that the Company cannot control or estimate precisely, such as future market conditions. The forward-looking statements made in this document constitute expectations for the future and should be regarded as such. Actual events or results may differ from those described in this document due to a number of risks and uncertainties described in Chapter 2 of the 2024 Universal Registration Document filed with the AMF on 1 April 2025 under registration number D.25-0209, available on the Company's website ( and that of the AMF ( All forward-looking statements included in this document are valid only as of the date of this press release. Clariane S.E. undertakes no obligation and assumes no responsibility to update the information contained herein beyond the requirements of applicable are cautioned not to place undue reliance on these forward-looking statements. Neither Clariane nor any of its directors, officers, employees, agents, affiliates or advisors accepts any responsibility for the reasonableness of any assumptions or opinions expressed or for the likelihood of any projections, prospects or performance being achieved. Any liability for such information is expressly excluded. Nothing in this document is, or should be construed as a promise or representation regarding the future. Furthermore, nothing contained in this document is intended to be or should be construed as a forecast of results. Clariane's past performance should not be taken as a guide to future performance. The main Alternative Performance Indicators (APIs), such as EBITDA, EBIT, net debt and financial leverage, are defined in the Universal Registration Document available on the Company's website at ClarianeClariane is the leading European community of care in times of vulnerability. It has operations in six countries: Belgium, France, Germany, Italy, the Netherlands and Spain. Relying on their diverse expertise, each year, the Group's 60,000 professionals provide services to 900,000 patients and residents in three main areas of activity: care homes (Korian, Seniors Residencias, etc.), healthcare facilities and services (Inicea, Ita, Grupo 5, etc.), and alternative living solutions (Petits-fils, Ages & Vie, etc.). In June 2023, Clariane became a purpose-driven company and added to its bylaws a new corporate purpose, common to all its activities: 'taking care of each person's humanity in times of vulnerability'.Clariane has been listed on Euronext Paris, Section B since November 2006. The Group joined the SBF 120 index and the CAC® SBT 1.5° index on 23 September ticker: - ISIN: Bisseuil Benoît Lesieur Head of Investor Relations Deputy Head of Investor Relations – ESG +33 6 58 60 68 69 +33 6 64 80 15 90 Julie Mary Florian Bachelet Press officer Press officer +33 6 59 72 50 69 +33 6 79 86 78 23 Attachment Press Release Clariane-renewal of drawdown under the RCFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
